BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 26950400)

  • 1. Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
    Liu N; Wang Y; Huang G; Ji C; Fan W; Li H; Cheng Y; Tian H
    Bioorg Chem; 2016 Apr; 65():146-58. PubMed ID: 26950400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
    Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
    Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors.
    Yang B; Wu Q; Huan X; Wang Y; Sun Y; Yang Y; Liu T; Wang X; Chen L; Xiong B; Zhao D; Miao Z; Chen D
    Bioorg Med Chem Lett; 2021 Feb; 33():127749. PubMed ID: 33340663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
    Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
    Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors.
    Chioua M; Samadi A; Soriano E; Lozach O; Meijer L; Marco-Contelles J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4566-9. PubMed ID: 19615897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3'-bipyridine derivatives as potential c-met inhibitors.
    Zhao S; Zhang Y; Zhou H; Xi S; Zou B; Bao G; Wang L; Wang J; Zeng T; Gong P; Zhai X
    Eur J Med Chem; 2016 Sep; 120():37-50. PubMed ID: 27187857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
    Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
    Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
    Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
    Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
    Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
    Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
    Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.